781 results match your criteria Surveillance for Recurrent Bladder Cancer


Incidence of fistula occurrence in patients with cervical cancer treated with bevacizumab: data from real-world clinical practice.

Int J Clin Oncol 2022 Jun 27. Epub 2022 Jun 27.

Department of Obstetrics and Gynecology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan.

Background: This study aimed to determine the incidence of pelvic fistulas in cervical cancer patients treated with bevacizumab in Japanese clinical practice.

Methods: A post-marketing surveillance (PMS) study was conducted between June 2016 and February 2018 to survey physicians who treated advanced or recurrent cervical cancer patients with bevacizumab (according to the product label). The clinical/treatment status of patients with pelvic fistulas was assessed in an additional retrospective case series study. Read More

View Article and Full-Text PDF

Case_series - Prioritizing bladder-sparing treatments in patients with urinary tract leiomyoma: A report of three cases and updated literature review.

Can Urol Assoc J 2022 Jun 9. Epub 2022 Jun 9.

Department of Urology, Westchester Medical Center, Valhalla, NY, United States.

Urinary tract leiomyomas are rare, benign mesenchymal tumors that are traditionally treated with complete surgical excision. We present three cases of urinary tract leiomyoma - two located in the bladder and one in the ureter. Both bladder leiomyomas were treated with transurethral resection of bladder tumor (TURBT) with no evidence of recurrent disease, while the upper tract leiomyoma was managed with surveillance by patient preference, which to our knowledge, has not been previously described. Read More

View Article and Full-Text PDF

Clinical Characteristics of Urinary Bladder Cancer in the Sudan; Evidence of Pathoetiology Changes.

Gulf J Oncolog 2022 May;1(39):16-20

Department of Surgery, Assafa College, Khartoum, Sudan.

Introduction: Bladder cancer (BC) is highly heterogeneous with regard to clinical course, etiology, histology, and geographic distribution. Recent clinical observations suggest changes in the pattern of BC in the Sudan perhaps due to lifestyle change following the massive displacement from rural to urban areas. The present study aimed to characterize the clinical profile of the BC among Sudanese patients and compare it with what has been previous reported. Read More

View Article and Full-Text PDF

Highly Sensitive and Specific Detection of Bladder Cancer via Targeted Ultra-deep Sequencing of Urinary DNA.

Eur Urol Oncol 2022 Apr 8. Epub 2022 Apr 8.

Bladder Cancer Research Centre, Institute of Cancer and Genomic Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK. Electronic address:

Background: There is an unmet need for an accurate, validated, noninvasive test for diagnosing and monitoring bladder cancer (BC). Detection of BC-associated mutations in urinary DNA via targeted deep sequencing could meet this need.

Objective: To test the ability of mutational analysis of urinary DNA to noninvasively detect BC within the context of haematuria investigations and non-muscle-invasive BC (NMIBC) surveillance. Read More

View Article and Full-Text PDF

Investigation of urinary volatile organic compounds as novel diagnostic and surveillance biomarkers of bladder cancer.

Br J Cancer 2022 Mar 29. Epub 2022 Mar 29.

Department of Molecular and Clinical Cancer Medicine, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, L69 3GE, UK.

Background: The diagnosis and surveillance of urothelial bladder cancer (UBC) require cystoscopy. There is a need for biomarkers to reduce the frequency of cystoscopy in surveillance; urinary volatile organic compound (VOC) analysis could fulfil this role. This cross-sectional study compared the VOC profiles of patients with and without UBC, to investigate metabolomic signatures as biomarkers. Read More

View Article and Full-Text PDF

Management, Surveillance Patterns, and Costs Associated With Low-Grade Papillary Stage Ta Non-Muscle-Invasive Bladder Cancer Among Older Adults, 2004-2013.

JAMA Netw Open 2022 03 1;5(3):e223050. Epub 2022 Mar 1.

Division of Urology, Department of Surgery, University of Texas Medical Branch, Galveston.

Importance: Low-risk non-muscle-invasive bladder cancer (NMIBC) is associated with extremely low rates of progression and cancer-specific mortality; however, patients with low-risk NMIBC may often receive non-guideline-recommended and potentially costly surveillance testing and treatment.

Objective: To describe current surveillance and treatment practices, cancer outcomes, and costs of care for low-grade papillary stage Ta (low-grade Ta) NMIBC and identify factors associated with increased cost of care.

Design, Setting, And Participants: This population-based cohort study identified 13 054 older adults (aged 66-90 years) diagnosed with low-grade Ta tumors in the Surveillance, Epidemiology and End Results-linked Medicare database from January 1, 2004, through December 31, 2013. Read More

View Article and Full-Text PDF

The Role of New Technologies in the Diagnosis and Surveillance of Non-Muscle Invasive Bladder Carcinoma: A Prospective, Double-Blinded, Monocentric Study of the XPERT© Bladder Cancer Monitor and Narrow Band Imaging© Cystoscopy.

Cancers (Basel) 2022 Jan 26;14(3). Epub 2022 Jan 26.

Department of Surgery, Division of Urology, Kantonsspital Baden, CH-5404 Baden, Switzerland.

Follow-up is essential for the early detection of recurrent non-muscle invasive bladder cancers (NMIBC). This study investigates the clinical relevance of new diagnostic tools such as an mRNA-based urine test (XPERT© Bladder Cancer Monitor, XBCM) and Narrow Band Imaging© (NBI) and compares them with the established follow-up diagnostics (white-light cystoscopy (WLC) and urine cytology). This was a prospective, double-blind, single-center study that involved patients undergoing NMIBC screening at a tertiary care center. Read More

View Article and Full-Text PDF
January 2022

Xpert Bladder Cancer Monitor May Avoid Cystoscopies in Patients Under "Active Surveillance" for Recurrent Bladder Cancer (BIAS Project): Longitudinal Cohort Study.

Front Oncol 2022 27;12:832835. Epub 2022 Jan 27.

Department of Urology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Humanitas Research Hospital, Milan, Italy.

Objectives: To test the hypothesis that patients under active surveillance (AS) for Non-muscle Invasive Bladder Cancer (NMIBC) who were negative on longitudinal re-testing by the Xpert Bladder Cancer Monitor (Xpert BC Monitor) assay may avoid unnecessary cystoscopies and urine cytology (UC).

Subjects/patients Or Materials And Methods: This is a prospective cohort study of patients enrolled in the AS protocol for recurrent NMIBC (Bladder Cancer Italian Active Surveillance, BIAS project), whose urine samples were analyzed by Xpert BC Monitor upon entry in the study (T0). Patients who had a negative Xpert test and did not fail AS, underwent additional Xpert tests after 4 (T1), 8 (T2), and 12 (T3) months. Read More

View Article and Full-Text PDF
January 2022

Bladder cancer detection in urine using DNA methylation markers: a technical and prospective preclinical validation.

Clin Epigenetics 2022 02 5;14(1):19. Epub 2022 Feb 5.

Department of Urology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.

Background: The development of accurate urinary biomarkers for non-invasive and cost-effective detection of primary and recurrent bladder tumours is recognized as one of the major clinical needs in bladder cancer diagnostics. The purposes of this study were (1) to validate the results of a previous technical comparison by determining the diagnostic performance of nine methylation markers in urine pellet compared to full void urine, and (2) to validate the diagnostic performance of the optimal marker panel GHSR/MAL from a previous exploratory study in a preclinical setting.

Methods: Urine samples of 108 patients with bladder cancer and 100 age- and gender-matched controls were prospectively collected for methylation analysis. Read More

View Article and Full-Text PDF
February 2022

Cadherin switches during epithelial-mesenchymal transition: CDH4/RCAD downregulation reduces bladder cancer progression.

Cell Oncol (Dordr) 2022 Feb 22;45(1):135-149. Epub 2022 Jan 22.

Cancer Biology and Epigenetics Group, Research Center of IPO Porto (CI-IPOP) / [email protected] (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto) / Porto Comprehensive Cancer Center (Porto.CCC), R. Dr. António Bernardino de Almeida, 4200-072, Porto, Portugal.

Purpose: Non-muscle invasive bladder cancer (NMIBC) is a highly recurrent disease that progresses to muscle-invasive bladder cancer (MIBC) in 5-25% of the cases. Epithelial-mesenchymal transition (EMT) has been associated with features of disease progression. Thus, we aimed to characterize the cadherin switch (CS), an EMT hallmark, and its regulatory mechanisms in bladder cancer (BlCa) progression, as well as the biological role of RCAD, a lesser-known cadherin, in bladder carcinogenesis. Read More

View Article and Full-Text PDF
February 2022

Immune profiles and DNA methylation alterations related with non-muscle-invasive bladder cancer outcomes.

Clin Epigenetics 2022 01 21;14(1):14. Epub 2022 Jan 21.

Department of Epidemiology, Geisel School of Medicine, Dartmouth College, Lebanon, NH, 03766, USA.

Background: Non-muscle-invasive bladder cancer (NMIBC) patients receive frequent monitoring because ≥ 70% will have recurrent disease. However, screening is invasive, expensive, and associated with significant morbidity making bladder cancer the most expensive cancer to treat per capita. There is an urgent need to expand the understanding of markers related to recurrence and survival outcomes of NMIBC. Read More

View Article and Full-Text PDF
January 2022

Hematuria following Post-Prostatectomy Radiotherapy: Incidence Increases with Long-Term Followup.

J Urol 2022 06 20;207(6):1236-1245. Epub 2022 Jan 20.

Department of Radiation and Cellular Oncology, University of Chicago, Chicago, Illinois.

Purpose: Hematuria following post-prostatectomy radiotherapy (PPRT) is inadequately characterized. We performed a consecutive cohort study of patients treated with PPRT at our institution to characterize this complication including impact on patient-reported quality of life.

Materials And Methods: Patients with potential followup ≥4 years following PPRT were identified. Read More

View Article and Full-Text PDF

Efficacy of pembrolizumab and comprehensive CD274/PD-L1 profiles in patients previously treated with chemoradiation therapy as radical treatment in bladder cancer.

J Immunother Cancer 2022 01;10(1)

Department of Urology, Osaka Medical and Pharmaceutical University, Takatsuki, Japan.

Background: Chemoradiation therapy (CRT) has been increasingly reported as a possible alternative to total cystectomy (TC) for localized bladder cancer (BC). Pembrolizumab is the standard of care for platinum-refractory metastatic urothelial carcinoma, although it is unknown whether the efficacy of pembrolizumab in patients previously treated with curative CRT varies from the results of benchmark trials.

Methods: We retrospectively assessed whether the survival benefit of pembrolizumab differs between patients previously treated with TC or CRT as radical treatment. Read More

View Article and Full-Text PDF
January 2022

Incidence and Outcomes Associated with 6,841 Isolated Distal Deep Vein Thromboses in Patients with 13 Common Cancers.

Thromb Haemost 2022 Jan 17. Epub 2022 Jan 17.

Division of Hematology and Oncology, Center for Oncology Hematology Outcomes Research and Training , University of California Davis School of Medicine, Sacramento, California, United States.

Introduction:  The epidemiology of isolated distal deep venous thrombosis (iDDVT) among cancer patients is not well described, particularly the incidence of recurrent venous thromboembolism (rVTE) and effect on mortality by cancer type.

Methods:  The cumulative incidence (CI) of iDDVT was determined for patients with 13 common cancers between 2005 and 2017 using the California Cancer Registry linked to the California Patient Discharge and Emergency Department Utilization datasets. The CI of rVTE was calculated and association of incident cancer-associated thrombosis (CT) location with rVTE was determined using Cox proportional hazards regression models. Read More

View Article and Full-Text PDF
January 2022

Open Radical Cystectomy versus Robot-Assisted Radical Cystectomy with Intracorporeal Urinary Diversion: Early Outcomes of a Single-Center Randomized Controlled Trial.

J Urol 2022 05 2;207(5):982-992. Epub 2022 Feb 2.

IRCCS "Regina Elena" National Cancer Institute, Department of Urology, Rome, Italy.

Purpose: Radical cystectomy (RC) with urinary diversion (UD) is still considered a complex surgery associated with significant morbidity. Open RC (ORC) remains the reference option of treatment, even if adoption of robot-assisted RC (RARC) is rapidly increasing. To date, all the available randomized controlled trials were characterized by an extracorporeal approach in performing UD, undermining potential benefits of a totally minimally invasive procedure. Read More

View Article and Full-Text PDF

Diagnostic performance of the Bladder EpiCheck methylation test and photodynamic diagnosis-guided cystoscopy in the surveillance of high-risk non-muscle invasive bladder cancer: A single centre, prospective, blinded clinical trial.

Urol Oncol 2022 03 12;40(3):105.e11-105.e18. Epub 2021 Dec 12.

Division of Urology Clinic, Department of Surgical and Biomedical Sciences, University of Perugia, Perugia, Italy.

Purpose: Currently, bladder cancer (BC) surveillance consists of periodic white light cystoscopy and urinary cytology (UC). However, both diagnostic tools have limitations. Therefore, to improve the management of recurrent BC, novel, innovative diagnostic tests are needed. Read More

View Article and Full-Text PDF

Outcomes of bacillus Calmette-Guérin therapy without a maintenance schedule for high-risk non-muscle-invasive bladder cancer in the second transurethral resection era.

Int J Urol 2022 03 11;29(3):251-258. Epub 2021 Dec 11.

Department of Urology, Hokkaido University Graduate School of Medicine, Japan.

Objectives: We examined the outcomes of eight weekly bacillus Calmette-Guérin induction therapy after second transurethral resection, and investigated risk factors for intravesical recurrence or disease progression in high-risk non-muscle-invasive bladder cancer patients.

Methods: This retrospective study included 146 high-risk non-muscle-invasive bladder cancer patients who received eight weekly bacillus Calmette-Guérin instillations without a maintenance schedule between 2000 and 2019. Intravesical recurrence-free and progression-free survival rates were evaluated using the Kaplan-Meier method. Read More

View Article and Full-Text PDF

Ileal conduit versus neobladder: A propensity score-matched analysis of the effect on renal function.

Int J Urol 2022 02 8;29(2):158-163. Epub 2021 Dec 8.

Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.

Objectives: To analyze the long-term effects of continent (neobladder) compared with incontinent (ileal conduit) urinary diversion.

Methods: We carried out a retrospective review of our departmental database. Estimated glomerular filtration rate was calculated using the Chronic Kidney Disease Epidemiology Collaboration equation. Read More

View Article and Full-Text PDF
February 2022

Blue versus white light for transurethral resection of non-muscle invasive bladder cancer.

Cochrane Database Syst Rev 2021 12 1;12:CD013776. Epub 2021 Dec 1.

Urology Section, Minneapolis VA Health Care System, Minneapolis, Minnesota, USA.

Background: Disease recurrence and progression remain major challenges in the treatment of non-muscle invasive bladder cancer (NMIBC). Blue light-enhanced transurethral resection of bladder cancer (TURBT) is an approach to improve staging and achieve a complete resection of NMIBC.

Objectives: To assess the effects of blue light-enhanced TURBT compared to white light-based TURBT in the treatment of NMIBC. Read More

View Article and Full-Text PDF
December 2021

A Retrospective Analysis of Clinical and Pathologic Characteristics of Recurrent Bladder Tumor in a Tertiary Hospital in Addis Ababa, Ethiopia.

Authors:
Andualem Beyene

Ethiop J Health Sci 2021 Jul;31(4):779-784

Dept. Surgery, School of Medicine, College of Health Sciences, Addis Ababa University.

Background: Previous recurrences, tumor category (Ta, T1), the presence of CIS with superficial bladder tumors, the number of tumors, tumor size and multiplicity are predictors of bladder tumor recurrence. Recurrence is better predicted by multiplicity, size and previous recurrence.

Methods: This is retrospective descriptive study. Read More

View Article and Full-Text PDF

An Unusual and Rare Metachronous Ipsilateral Ureteric Stump Metastasis Post Radical Nephrectomy.

Cureus 2021 Sep 5;13(9):e17727. Epub 2021 Sep 5.

Urology, Arrowe Park Hospital, Wirral University Teaching Hospital National Health Service Foundation Trust, Birkenhead, GBR.

We report a case of recurrence of chromophobe renal cell cancer in the ipsilateral ureteric stump eight years later after the primary tumor was excised successfully. Before this detection of the recurrence, the patient had presented with recurrent episodes of hematuria four years after the radical nephrectomy was performed and the investigations were inconclusive. Eventually, the lesion was detected on flexible cystoscopy in the area of the right ureteric orifice protruding in the bladder. Read More

View Article and Full-Text PDF
September 2021

Expression of p53 Protein Associates with Anti-PD-L1 Treatment Response on Human-Derived Xenograft Model of GATA3/CR5/6-Negative Recurrent Nonmuscular Invasive Bladder Urothelial Carcinoma.

Int J Mol Sci 2021 Sep 12;22(18). Epub 2021 Sep 12.

Department of Urology, Andrology and Oncology, Pirogov Russian National Research Medical University, 1 Ostrovityanova Street, 117997 Moscow, Russia.

Background: The possible involvement of p53 signaling, FGFR3 expression, and mutation rates in the prediction of the NMIBC anti-PD-L1 treatment response needs to be clarified. The main aim of our study was to explore predictive value of p53 expression, FGFR3 expression, and its gene mutation status for the therapeutic success of anti-PD-L1 treatment in the patient-derived murine model of recurrent high-PD-L1(+) GATA3(-)/CR5/6(-) high-grade and low-grade NMIBC.

Methods: twenty lines of patient-derived xenografts (PDXs) of relapsed high-PD-L1(+) double-negative NMIBC were developed, of which 10 lines represented high-grade tumors and the other ones-low-grade bladder cancer. Read More

View Article and Full-Text PDF
September 2021

Clinical, Pathological, and Prognostic Analysis of Urachal Carcinoma.

Urol Int 2022 25;106(2):199-208. Epub 2021 Aug 25.

Department of Urology, Peking University First Hospital, Beijing, China.

Objective: The aim of this study was to improve understanding the clinical, pathologic, and prognostic features of urachal carcinoma (UrC), a retrospectively descriptive study was done in 2 clinical centers.

Methods: After excluding the 2 missed patients, the clinical and pathological data of 59 patients with UrC, who were diagnosed or treated at 2 clinical centers between 1986 and 2019, was retrospectively analyzed. SPSS 22. Read More

View Article and Full-Text PDF

[NEOADJUVANT CHEMOTHERAPY BEFORE RADICAL CYSTECTOMY - MIGHT IT BE OFFERED SELECTIVELY?]

Harefuah 2021 Sep;160(9):559-564

Department of Urology, Hadassah University Hospital, Jerusalem.

Introduction: Neoadjuvant cisplatin-based chemotherapy prior radical cystectomy is the standard of care in patients with a muscle invasive bladder cancer. It is intended to treat micro-metastases. However, most patients do not develop metastases even without chemotherapy and are receiving this treatment in vain. Read More

View Article and Full-Text PDF
September 2021

Prospective Phase II Study to Evaluate Response to Two Induction Courses (12 intravesical instillations) of BCG Therapy for High-risk Non-muscle-invasive Bladder Cancer.

Urology 2021 11 15;157:197-200. Epub 2021 Jul 15.

Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY.

Objective: To test whether 2 sequential BCG-induction courses improve the response of high-risk non-muscle invasive bladder cancer. Achieving a complete response (CR) to BCG is critical to disease-free survival. Patients with preexisting BCG-specific immunity owing to prior exposure to BCG have longer disease-free survival than BCG-naïve patients likely due to heterologous immunity from the initial priming of the immune system. Read More

View Article and Full-Text PDF
November 2021

Association of the Healthy Nordic Food Index with risk of bladder cancer: a case-control study.

Eur J Clin Nutr 2022 03 6;76(3):482-486. Epub 2021 Jul 6.

Department of Community Nutrition, National Nutrition and Food Technology Research Institute, Faculty of Nutrition Sciences and Food Technology, Shahid Behehshti University of Medical Sciences, Tehran, Iran.

Background: Bladder cancer (BC) is the ninth recurrent neoplasm in the world. In Iran, incidence of BC is the third most common among men. Few dietary patterns are related to reduced carcinogenesis and consequently are amenable to modification in order to reduce the BC risk. Read More

View Article and Full-Text PDF

Non-muscle-invasive bladder cancer: An overview of potential new treatment options.

Urol Oncol 2021 10 22;39(10):642-663. Epub 2021 Jun 22.

Perlmutter Cancer Center, an NCI-designated Comprehensive Cancer Center Goldstein Bladder Cancer Program, NYU Langone Health, NYU Urology Associates, New York University, New York, NY, USA. Electronic address:

Aim: This review article summarizes the current clinical practice guidelines around disease definitions and risk stratifications, and the treatment of non-muscle-invasive bladder cancer (NMIBC). Recently completed and ongoing clinical trials of novel and investigational therapies in Bacillus Calmette-Guérin (BCG)-naïve, BCG-recurrent, and BCG-unresponsive patient populations are also described, e.g. Read More

View Article and Full-Text PDF
October 2021

Risk factors for residual disease at re-TUR in a large cohort of T1G3 patients.

Actas Urol Esp (Engl Ed) 2021 Jul-Aug;45(6):473-478. Epub 2021 Jun 17.

Department of Urology, Fundacio Puigvert, University of Barcelona, Barcelona, Spain.

Introduction And Objectives: The goals of transurethral resection of a bladder tumor (TUR) are to completely resect the lesions and to make a correct diagnosis in order to adequately stage the patient. It is well known that the presence of detrusor muscle in the specimen is a prerequisite to minimize the risk of under staging. Persistent disease after resection of bladder tumors is not uncommon and is the reason why the European Guidelines recommended a re-TUR for all T1 tumors. Read More

View Article and Full-Text PDF
October 2021